Background/Aim: Due to the SARS-CoV-2 pandemic, many scientific committees proposed neoadjuvant therapy (NACT) bridging treatment as a novel strategy and indication. The aim of the study was to evaluate the impact of COVID-19 pandemic on breast cancer patients undergoing NACT. Patients and Methods: All breast cancer patients referred to two Breast Units during COVID-19-pandemic were enrolled. Results: Out of 814 patients, 43(5.3%) were enrolled in the COVID-19-group and compared with 94 (7.9%) similar Pre-COVID-19 patients. We observed a reduction in the number of patients undergoing NACT, p=0.0019. No difference was reported in terms of clinical presentation, indications, and tumor response. In contrast, a higher number of vascular adverse events was reported (6.9% vs. 0% p=0.029). Immediate breast cancer reconstructions following invasive surgery suffered a significant slowdown (5.9% vs. 47.7%, p=0.019). Conclusion: COVID-19 caused a reduction in the number of patients undergoing NACT, with no changes in terms of indications, clinical presentation, and tumor response. Furthermore, there was an increased incidence of vascular events.

Impact of covid-19 pandemic on surgical breast cancer patients undergoing neoadjuvant therapy: A multicentric study / Vanni, G.; Pellicciaro, M.; Combi, F.; Papi, S.; Materazzo, M.; Segattini, S.; Rizza, S.; Chiocchi, M.; Perretta, T.; Meucci, R.; Portarena, I.; Pistolese, C. A.; Ielpo, B.; Campanelli, M.; Lisi, G.; Chiaravalloti, A.; Tazzioli, G.; Buonomo, O. C.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 41:9(2021), pp. 4535-4542. [10.21873/anticanres.15265]

Impact of covid-19 pandemic on surgical breast cancer patients undergoing neoadjuvant therapy: A multicentric study

Combi F.;Papi S.;Segattini S.;Campanelli M.;Lisi G.;Tazzioli G.;
2021

Abstract

Background/Aim: Due to the SARS-CoV-2 pandemic, many scientific committees proposed neoadjuvant therapy (NACT) bridging treatment as a novel strategy and indication. The aim of the study was to evaluate the impact of COVID-19 pandemic on breast cancer patients undergoing NACT. Patients and Methods: All breast cancer patients referred to two Breast Units during COVID-19-pandemic were enrolled. Results: Out of 814 patients, 43(5.3%) were enrolled in the COVID-19-group and compared with 94 (7.9%) similar Pre-COVID-19 patients. We observed a reduction in the number of patients undergoing NACT, p=0.0019. No difference was reported in terms of clinical presentation, indications, and tumor response. In contrast, a higher number of vascular adverse events was reported (6.9% vs. 0% p=0.029). Immediate breast cancer reconstructions following invasive surgery suffered a significant slowdown (5.9% vs. 47.7%, p=0.019). Conclusion: COVID-19 caused a reduction in the number of patients undergoing NACT, with no changes in terms of indications, clinical presentation, and tumor response. Furthermore, there was an increased incidence of vascular events.
2021
41
9
4535
4542
Impact of covid-19 pandemic on surgical breast cancer patients undergoing neoadjuvant therapy: A multicentric study / Vanni, G.; Pellicciaro, M.; Combi, F.; Papi, S.; Materazzo, M.; Segattini, S.; Rizza, S.; Chiocchi, M.; Perretta, T.; Meucci, R.; Portarena, I.; Pistolese, C. A.; Ielpo, B.; Campanelli, M.; Lisi, G.; Chiaravalloti, A.; Tazzioli, G.; Buonomo, O. C.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 41:9(2021), pp. 4535-4542. [10.21873/anticanres.15265]
Vanni, G.; Pellicciaro, M.; Combi, F.; Papi, S.; Materazzo, M.; Segattini, S.; Rizza, S.; Chiocchi, M.; Perretta, T.; Meucci, R.; Portarena, I.; Pistolese, C. A.; Ielpo, B.; Campanelli, M.; Lisi, G.; Chiaravalloti, A.; Tazzioli, G.; Buonomo, O. C.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1255938
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact